Exactly right. Nobody is interested in bisantrene as a less cardiotoxic alternative to doxorubicin, they are interested because they can keep using doxorubicin and gain the potential of cardioprotection and increased anticancer activity.
While the data Moleculin have presented is very interesting, the market doesn't seem to care and their MC is only US$10m.
Cardioprotection thread, page-406
-
- There are more pages in this discussion • 434 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.61 |
Change
-0.025(1.53%) |
Mkt cap ! $278.5M | |||
| Open | High | Low | Value | Volume |
| $1.66 | $1.69 | $1.59 | $154.5K | 94.54K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2061 | $1.61 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.64 | 917 | 1 |
View Market Depth
| Last trade - 10.29am 25/07/2024 (20 minute delay) ? |
| RAC (ASX) Chart |